SK Bioscience
Launch date
Employees
Market cap
$3.6b
Enterprise valuation
$2.6b (Public information from Sep 2024)
Share price
KRW55000 302440.KS
Seongnam-si Gyeonggi-do (HQ)
Financials
Estimates*
| KRW | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 225.6b | 929.0b | 456.7b | 369.5b | 208m | 291m | 355m |
| % growth | 23 % | 312 % | (51 %) | (19 %) | (100 %) | 40 % | 22 % |
| EBITDA | 60.7b | 497.6b | 164.8b | 54.4b | (6.7m) | (6.6m) | 27.6m |
| % EBITDA margin | 27 % | 54 % | 36 % | 15 % | (3 %) | (2 %) | 8 % |
| Profit | 32.9b | 355.1b | 122.5b | 22.3b | (36.9m) | (5.7m) | 26.6m |
| % profit margin | 15 % | 38 % | 27 % | 6 % | (18 %) | (2 %) | 7 % |
| EV / revenue | - | 0.0x | 0.0x | 0.0x | 17.8x | 12.3x | 10.7x |
| EV / EBITDA | - | 0.0x | 0.0x | 0.1x | -552.8x | -537.7x | 137.3x |
| R&D budget | 26.0b | 47.3b | 58.0b | 85.7b | - | - | - |
| R&D % of revenue | 12 % | 5 % | 13 % | 23 % | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | N/A | IPO | |
* | N/A | Post IPO Equity | |
| Total Funding | - | ||
Recent News about SK Bioscience
EditInvestments by SK Bioscience
Edit
ACQUISITION by SK Bioscience Jun 2024
